Ranitidine products recalled from the market
On Apr. 1, 2020, the U.S. Food and Drug Administration (FDA) widened its recall scope for ranitidine (brand name Zantac) products, requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately.
Products are being recalled due to the detection of a trace amount of an unexpected impurity, N-Nitrosodimethylamine (NDMA).
Due to the recall, ranitidine products are no longer available for new or existing prescriptions or OTC use.
We're notifying members
Claims data shows us that 2,200 members are impacted by this recall, all of which will receive letters alerting them to the recall within the next week. Additionally, all providers who had originally prescribed this medication will receive a letter describing the recall.
In the member letter, we're encouraging members to contact their physician or pharmacist and to review the FDA website for additional information.